-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26

Benzinga·06/30/2026 12:56:16
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.